CAB-LA + RPV-LA

cabotegravir long-acting + rilpivirine long-acting · ViiV Healthcare

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAB-LA + RPV-LA, covering 2023-09-13 to 2023-09-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed [Phase 3]

See pricing